Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
2(18%)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_1
2
18%
Ph phase_2
1
9%
Ph phase_3
1
9%
Ph phase_4
5
45%

Phase Distribution

2

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
5(45.5%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 21 (9.1%)
Phase 31 (9.1%)
Phase 45 (45.5%)
N/A2 (18.2%)

Trials by Status

unknown19%
terminated218%
completed873%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

NCT03439943
completedphase_4

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

NCT02049034
completednot_applicable

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

NCT02640118
terminatedphase_1

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

NCT02231658
completednot_applicable

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

NCT02745470
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03439943Phase 2

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

Completed
NCT02049034Phase 4

Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

Completed
NCT02640118Not Applicable

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

Completed
NCT02231658Phase 1

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Terminated
NCT02745470Not Applicable

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

Completed
NCT02168491Phase 3

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

Completed
NCT02767596Phase 4

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

Terminated
NCT01973231Phase 4

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Completed
NCT02276196Phase 4

Effect of LIXIsenatide on the Renal System

Completed
NCT02020629Phase 4

Study on Lixisenatide and Counterregulation to Hypoglycemia

Completed
NCT02308254Phase 1

Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11